Company Description

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors.

The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.

Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.

The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Silexion Therapeutics Corp

Country	Israel
Founded	2008
Industry	Biotechnology
Sector	Healthcare
CEO	Ilan Hadar

Contact Details

Address: The Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Medical Center Jerusalem, 9112001 Israel
Phone	972 2 674 3430
Website	silexion.com

Stock Details

Ticker Symbol	SLXN
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0002022416
ISIN Number	KYG1281K1067
SIC Code	2836

Key Executives

Name	Position
Mirit Horenshtein Hadar	Executive Vice President of Finance Affairs, Chief Financial Officer and Secretary
Dr. Mitchell Shirvan M.B.A., Ph.D.	Chief Scientific and Development Officer

Latest SEC Filings

Date	Type	Title
Dec 17, 2024	8-K	Current Report
Dec 16, 2024	8-K	Current Report
Dec 10, 2024	424B3	Prospectus
Dec 10, 2024	424B3	Prospectus
Dec 10, 2024	8-K	Current Report
Nov 29, 2024	424B3	Prospectus
Nov 29, 2024	424B3	Prospectus
Nov 29, 2024	8-K	Current Report
Nov 27, 2024	8-K	Current Report
Nov 22, 2024	424B3	Prospectus

View All SEC Filings